Johnson & Johnson files for CAPLYTA approval in bipolar mania
- Johnson & Johnson submitted a supplemental New Drug Application to the U.S. FDA for CAPLYTA (lumateperone) in adults with bipolar I mania.
- The application is supported by two Phase 3 trials of once-daily 42 mg CAPLYTA over three weeks.
- Both trials showed significant improvement versus placebo, with manic symptoms improving from Day 3.
- CAPLYTA is currently approved for schizophrenia, bipolar depression and adjunctive treatment of major depressive disorder in adults.
FDA application
Johnson & Johnson submitted a supplemental New Drug Application to the U.S. Food and Drug Administration seeking approval of CAPLYTA (lumateperone) for manic or mixed episodes associated with bipolar I disorder in adults. If approved, this would be the medicine’s fifth approved adult use. It is not currently approved for bipolar mania.
Phase 3 results
The application is based on two randomized, double-blind, placebo-controlled Phase 3 studies. Adults received once-daily CAPLYTA 42 mg or placebo for three weeks. In both studies, CAPLYTA met the primary and key secondary endpoints, showing significant improvement in manic symptoms and overall illness severity compared with placebo. Symptom improvement was observed by Day 3 and continued through Week 3. The medicine was well tolerated, with low discontinuation rates and a safety profile consistent with previous studies.
Current indications
CAPLYTA is approved for adults with depressive episodes associated with bipolar I or II disorder, either alone or with lithium or valproate; as an adjunct to antidepressants for major depressive disorder; and for schizophrenia.
Source: J&J